Since 2016, the WHO has included molecular parameters in the assessment, and in 2021, the parameters were further updated to include more molecular markers, e.g., IDH mutation, into the classification of gliomas, which are also obtained through histological examination of tumour tissue [3,4]. Here, IDH1 is linked to glioma.